Tirofiban Tops Cangrelor, Prasugrel in Inhibiting Platelet Aggregation in STEMI Patients
Chewed prasugrel proved no more effective at inhibiting platelets than whole-swallowed prasugrel; prasugrel in either form was inferior to both tirofiban and cangrelor.
Tirofiban showed the best inhibition of platelet aggregation (IPA), outperforming both cangrelor and prasugrel in patients with ST-elevation myocardial infarction (STEMI) undergoing primary percutaneous coronary intervention (PCI), according to results of the FABOLUS-FASTER randomized controlled trial presented Saturday at the PCR e-Course.